Phoenix Biomolecular

Phoenix Biomolecular Group is a private biotechnology company focused on the development of metabolic oncology therapeutics. The company specializes in targeting the Warburg effect, a metabolic hallmark of cancer where tumor cells rely on glycolysis for energy and biomass production. Their lead program, PBG-001, is a small molecule inhibitor of the enzyme Lactate Dehydrogenase A (LDH-A), which is essential for the metabolic reprogramming of aggressive cancers. Phoenix Biomolecular Group primarily targets high-unmet-need indications such as triple-negative breast cancer and pancreatic cancer. By disrupting these metabolic pathways, the company aims to provide new treatment options that can overcome resistance to conventional therapies. The company is headquartered in Carlsbad, California.